StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury

http://www.marketwatch.com/story/stemcells-inc-provides-update-on-its-phase-iii-study-in-spinal-cord-injury-2014-05-19?reflink=MW_news_stmp

StemCells, Inc. STEM +0.71% announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains…